Logo

Suggestions

  • Cancer Disparities
  • Opinion
  • Conferences
  • News
  • Patient Corner
  • About
    • Contact
    • Article Submission
  • Top Headlines
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • GI Malignancies
      • Melanoma & Skin Cancer
      • GU Malignancies
      • Gynecologic Oncology
      • Hematologic Malignancies
      • Lung Cancer
  • Expert Opinion
  • Video News
  • New Approvals
  • Cancer Disparities
  • Patient Corner
  • Subscribe

Logo

cancer treatment

FDA_Approved
February 7, 2023
Breast Cancer/New Drug Applications

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and

Hematologic Malignancies/Opinion

AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia

Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the phase III AGILE trial reported in the New England Journal of Medicine, Pau Montesinos, M.D., Ph.D., and colleagues found that the

January 31, 2023

Chemotherapy Free Ph+ ALL Induction? The Promise of Ponatinib plus Blinatumomab

Hematologic Malignancies/Opinion

Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center   Philadelphia positive acute lymphoblastic leukemia treatment has been driven by the combination of

FDA Approves an Expanded Indication of Abemaciclib with Endocrine Therapy for Early Breast Cancer

New Drug Applications

On March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patients with early,

FDA_Approved
New Drug Applications

FDA Approves an Expanded Indication of Abemaciclib with Endocrine Therapy for Early Breast Cancer

On March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patients with early, hormone receptor (HR)-positive, human epidermal growth factor receptor

More
by Tiani Grosso
March 7, 2023
Hematologic Malignancies/Opinion

Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma

By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health   A multicenter retrospective study, which was conducted at 11 academic centers across the United States, reported a

More
by Tiani Grosso
February 27, 2023
Hematologic Malignancies/Opinion

KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?

By Dr. Harsh Parmar Hackensack Meridian Health   In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US,

More
by Tiani Grosso
February 17, 2023
FDA_Approved
Breast Cancer/New Drug Applications

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer

On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and

More
by Tiani Grosso
February 7, 2023
Dr_Luke_Fletcher
Hematologic Malignancies/Opinion

Chemotherapy Free Ph+ ALL Induction? The Promise of Ponatinib plus Blinatumomab

Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center   Philadelphia positive acute lymphoblastic leukemia treatment has been driven by the combination of tyrosine kinase inhibitors targeting BCR-ABL in conjunction with

More
by Tiani Grosso
January 31, 2023
Hematologic Malignancies/Opinion

AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia

Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the phase III AGILE trial reported in the New England Journal of Medicine, Pau

More
by Tiani Grosso
January 31, 2023
Cancer Research/Volunteer Spotlight

Binaytara Foundation Starts Development of Cancer App

The Foundation Participated in Hackathon by Microsoft to Create Prototype The Binaytara Foundation teamed up with employees of Microsoft to work on the development of our Cancer Crush app in this year’s

More
by Staff Writer - The Cancer News
October 12, 2022
dr.suwal
Nepal Cancer Center/News/Volunteer Spotlight

First Head and Neck Surgery Program in Madhesh State of Nepal at the Binaytara Foundation Cancer Center Impacting Community

Dr. Rubina Suwal of the Binaytara Foundation Cancer Center performs successful oral cancer surgery for patient in local community

More
by Staff Writer - The Cancer News
September 30, 2022

your advertisement here

you may also like...

  • Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial
  • FDA_Approved
    FDA Approves Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
  • Dr. Rubina Suwal of the Binaytara Foundation Cancer Center Receives ASCO International Innovation Grant
  • Dr_Luke_Fletcher
    Zuma 7 trial shows statistically significant overall survival benefit for yescarta
  • Biomarker Testing in Advanced Non-Small Cell Lung Cancer

All Categories

  • Awareness
  • Breast Cancer
  • Cancer Disparities
  • Cancer Research
  • Conference 2023
  • Conferences
  • Events
  • GI Malignancies
  • GU Malignancies
  • Hematologic Malignancies
  • Journal
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Nepal Cancer Center
  • New Drug Applications
  • News
  • Opinion
  • Patient Corner
  • Spotlights
  • Uncategorized
  • Updates
  • Video News
  • Volunteer Spotlight

Search By Keyword

2022 Summit on Cancer Health Disparities ASCO award Binaytara foundation Binaytara Foundation Cancer Center Binaytara Foundation education academy breast cancer BTF cancer cancer care cancer disparities cancer research cancer treatment cancer treatment in Nepal CME community oncologists conference Conferences continuing education Dr. Binay Shah Dr. Rubina Suwal events Expert Opinion faculty highlight FDA approved head & neck cancer surgery in Nepal healthcare equity hematological malignancies Lung cancer Nepal Nepal cancer care oncology oncology CME Opinion SCHD upcoming conferences video news Volunteer

We Transform Cancer Care

Dissect complex information on cancer and disseminate knowledge to healthcare professionals, patients, and caregivers. We want to improve patient outcomes.
Cover the latest research to promote precision oncology and patient-centered care.
Questions? Contact us -
[email protected]

Social Media

Advertisement


Footer Logo
  • Facebook
  • Twitter
  • LinkedIn
  • Email

© 2023 - All Rights Reserved. Binaytara Foundation

  • About
  • Submit an Article
  • Subscribe for updates
  • Editorial Board
  • Privacy Policy
  • Contact
  • Home
  • Top Headlines
    • Awareness
    • Video News
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • Melanoma & Skin Cancer
      • GI Malignancies
      • Lung Cancer
      • Hematologic Malignancies
      • Gynecologic Oncology
      • GU Malignancies
  • New in Cancer Care
  • Conferences
    • Hemotology & Oncology Conference Calendar
    • Conference Calendar
    • Conference Coverage
  • New Approvals
  • Contact us
  • Submit an article